Phone: 440.834.0011
info@bccns.org

Basal Cell Carcinoma Nevus Syndrome Life Support Network

Important Announcement

FDA APPROVES ERIVEDGE (VISMODEGIB) CAPSULE, THE FIRST MEDICINE FOR ADULTS WITH ADVANCED BASAL CELL CARCINOMA

--Erivedge is a First-in-Class Hedgehog Pathway Inhibitor That Helps Shrink Disfiguring or Potentially Life-Threatening Lesions in Advanced Skin Cancer --

South San Francisco, Calif. -- January 30, 2012 -- Genentech, a member of the Roche Group, today announced that ErivedgeTM (vismodegib) capsule was approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with basal cell carcinoma (BCC), that has spread to other parts of the body or that has come back after surgery or that their healthcare provider decides cannot be treated with surgery or radiation. Erivedge is the first FDA-approved medicine for people with advanced forms of the most common skin cancer. It is a capsule that is taken orally once-a-day.

For more information and to view the entire press release, click here.

Our Purpose:

To provide health care, counseling, and support services to children and adults manifesting the inherited genetic disorder most commonly known as Basal Cell Carcinoma Nevus Syndrome (BCCNS), with particular focus on early diagnosis and treatment for children evidencing the initial onset of BCCNS.

To develop information about the medical conditions and disorders experienced by those living with BCCNS; to share this information with clinics and health care providers treating patients with BCCNS and other similar disorders; and to undertake a collaborative approach to the diagnosis, treatment, prevention, and cure of the disorders encompassed by BCCNS.

To provide a supportive environment for families to seek treatment for their children and other family members, and to train physicians, nurses, and other healthcare providers to communicate more effectively with BCCNS patients and their families, as well as other similarly affected populations.

We Will Provide:

Individual and group support and counseling designed to assist families in coping with BCCNS.

Opportunities to meet, communicate, and network with similarly situated children and their families at Network-sponsored events, including multimedia presentations and other means of communication.

Referrals to specialists and/or healthcare facilities most able to diagnose and treat effectively the disorders and diseases encompassed by BCCNS.

Education, resources and research
about the genetic disorder known as
BCCNS, and similar or allied disorders.

The information in this web site is for educational purposes only, and is not providing medical or professional advice.
It should not be used for diagnosing or treating a health problem or disease. It is not a substitute for
professional medical care. If you have or suspect you might have any health problems, you should consult a physician.

Home About BCCNS Make a Donation Contact Us

	Phone: 440.834.0011 info@bccns.org

Chat in our Online Forum Join our Facebook group Stay updated with Twitter

Home About Us About the Network Our Mission & History Board of Trustees Medical Advisory Board Testimonial Stories Just For Kids About BCCNS Manifestations FAQs Glossary of Terms Educational Articles PowerPoint Presentations DVDs Treatments & Research Dermatological Treatments Oral Surgery Treatments Clinical Trials Physician Referral List List of Links Get Involved Events Forum Newsletters Spread the Sunshine Emotional Expressions Volunteering & Fundraising Make a Donation Contact Us Contact Info & Directions Survey Register as a Member Register as a Medical Professional Recommend a Medical Professional
Basal Cell Carcinoma Nevus Syndrome Life Support Network
Important Announcement FDA APPROVES ERIVEDGE (VISMODEGIB) CAPSULE, THE FIRST MEDICINE FOR ADULTS WITH ADVANCED BASAL CELL CARCINOMA --Erivedge is a First-in-Class Hedgehog Pathway Inhibitor That Helps Shrink Disfiguring or Potentially Life-Threatening Lesions in Advanced Skin Cancer -- South San Francisco, Calif. -- January 30, 2012 -- Genentech, a member of the Roche Group, today announced that ErivedgeTM (vismodegib) capsule was approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with basal cell carcinoma (BCC), that has spread to other parts of the body or that has come back after surgery or that their healthcare provider decides cannot be treated with surgery or radiation. Erivedge is the first FDA-approved medicine for people with advanced forms of the most common skin cancer. It is a capsule that is taken orally once-a-day. For more information and to view the entire press release, click here.
Our Purpose: To provide health care, counseling, and support services to children and adults manifesting the inherited genetic disorder most commonly known as Basal Cell Carcinoma Nevus Syndrome (BCCNS), with particular focus on early diagnosis and treatment for children evidencing the initial onset of BCCNS. To develop information about the medical conditions and disorders experienced by those living with BCCNS; to share this information with clinics and health care providers treating patients with BCCNS and other similar disorders; and to undertake a collaborative approach to the diagnosis, treatment, prevention, and cure of the disorders encompassed by BCCNS. To provide a supportive environment for families to seek treatment for their children and other family members, and to train physicians, nurses, and other healthcare providers to communicate more effectively with BCCNS patients and their families, as well as other similarly affected populations. We Will Provide: Individual and group support and counseling designed to assist families in coping with BCCNS. Opportunities to meet, communicate, and network with similarly situated children and their families at Network-sponsored events, including multimedia presentations and other means of communication. Referrals to specialists and/or healthcare facilities most able to diagnose and treat effectively the disorders and diseases encompassed by BCCNS. Education, resources and research about the genetic disorder known as BCCNS, and similar or allied disorders.
Register as Medical Professional Register as a Member Recommend a Medical Professional
The information in this web site is for educational purposes only, and is not providing medical or professional advice. It should not be used for diagnosing or treating a health problem or disease. It is not a substitute for professional medical care. If you have or suspect you might have any health problems, you should consult a physician. Home About BCCNS Make a Donation Contact Us